TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01046721
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous administration of 0.9% saline solution (0.02 ml)
Study: NCT01637259
Drug: Arm 2 boosted protease inhibitors and maraviroc
Normalized name: Protease inhibitors
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PI + maraviroc
Study: NCT01637259
Drug: Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NRTI + maraviroc
Study: NCT03007537
Drug: Erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10000 IU erythropoietin, subcutaneous injection
Study: NCT03007537
Drug: 0.9% sodium chloride
Normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.9% sodium chloride 1ml, subcutaneous injection
Study: NCT03272698
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Ketamine 0.50 mg/kg
Study: NCT00201838
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The starting dose will be 1000mg/m2 IV, weekly x 7 with a one week rest followed by weekly x 3 with one week rest for the remainder of treatment.
Study: NCT00201838
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept will be self administered subcutaneously by patients with injections 11 prepared by the investigational pharmacy, beginning 7 days prior to the first dose of gemcitabine and continued twice weekly for the duration of the study.
Study: NCT04635566
Drug: mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.
DrugBank: Mebeverine (DB12554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mebeverine 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening. 200 mg sustained-release (Coloverine® SR, Chemipharm pharmaceutical, Egypt) one time/day at the evening.
Study: NCT04608513
Drug: ACT-1014-6470
Normalized name: ACT-541468
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft capsules for oral administration
Study: NCT00005007
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02777229
Drug: Dolutegravir 50 mg
Normalized name: dolutegravir 50 MG
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tablet once a day
Study: NCT02777229
Drug: Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed dose combination, 1 tablet once a day
Study: NCT01946971
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02512497
Drug: Romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part 1: Romidepsin dosed per actual body weight/actual body surface area. Romidepsin administered on Day -6, -5, -4, and -3 at escalating doses of 1 mg/m2, 2 mg/m2, and 3 mg/m2 by vein to determine the maximal tolerated dose.~Romidepsin Maintenance Therapy - Part 2: Starting between Day +28 and Day +100, if participant is eligible based on disease status, they will continue to receive Romidepsin 8 mg/m2 by vein over 1 hour on Day 1 of each 2-week cycle.
Study: NCT02512497
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part 1: First 2 doses of Busulfan of 80 mg/m2 administered on day -13 and -12. Busulfan administered at the dose calculated to achieve a total (including first two doses delivered on Day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic (PK) studies. An additional standard of care (SOC) option is now added for those with an HCT-CI \>4 or deemed unfit by the investigator to receive full dose (AUC 5000 umol-min) Time-Sequential (TS) Busulfan. SOC busulfan is administered per OSU SCT SOP with a targeted AUC of 4000 umol-min/day for a total exposure of 16,000 umol-min +/- 12% u-Mol-min based upon PK studies. Busulfan 'test-dose' PK studies will be performed prior to administration of full dose of busulfan per SOC. Romidepsin and fludarabine will be administered in an identical fashion using the SOC busulfan as with the TS busulfan. TS busulfan method of busulfan administration will be the preferred method of conditioning therapy for patients enrolled.
Study: NCT02512497
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: Fludarabine 40 mg/m2 by vein on Days -6 to -3.
Study: NCT02512497
Drug: Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receiving a graft from a matched unrelated donor receive rabbit Thymoglobulin; 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
Study: NCT02985957
Drug: Cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT02985957
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT00544830
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00544830
Drug: Goserelin Acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given SC
Study: NCT00544830
Drug: Leuprolide Acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given via injection
Study: NCT02951884
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An injection of 20cc bupivacaine 0.5% with 1:200,00 epinephrine
Study: NCT04213794
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Undergo HIPEC with doxorubicin and cisplatin
Study: NCT04213794
Drug: Hyperthermic Intraperitoneal Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo HIPEC with doxorubicin and cisplatin
Study: NCT04213794
Drug: Sodium Thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02777229
Drug: Efavirenz 400 mg
Normalized name: efavirenz 400 MG
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablets once a day
Study: NCT02300818
Drug: Seawater eyedrops
Normalized name: sodium chloride
DrugBank: Water (DB09145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eye-drops daily 1 time a day for 12 weeks
Study: NCT01462474
Drug: Famitinib
Normalized name: Famitinib
DrugBank: Famitinib (DB11741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either at 12.5 mg, 16.5 mg、20 mg or 25 mg qd p.o., 2 weeks before concurrent chemoradiotherapy and D1-D49, exception D1, D22, and D43.
Study: NCT01462474
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m2, D1, D22, and D43(q3w)
Study: NCT04225039
Drug: INCAGN01876
Normalized name: Incagn01876
DrugBank: Ragifilimab (DB18853)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg IV neoadjuvant treatment; 300 mg adjuvant treatment
Study: NCT03456063
Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered as intravenous (IV) infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle (every 3 weeks) for 4 cycles during the neoadjuvant treatment phase~Atezolizumab will be administered as IV infusion at a dose of 1200 milligrams (mg) every 3 weeks for 16 cycles during the post-operative adjuvant phase
Study: NCT03456063
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel 100 mg/m\^2 will be administered intravenously on Days 1, 8, and 15 of each 21 day cycle for 4 cycles during the neoadjuvant treatment phase
Study: NCT03456063
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Study: NCT03456063
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin initial target AUC of 6 mg/mL/min will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Study: NCT03456063
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Study: NCT03456063
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1250 mg/m\^2 will be administered intravenously on Day 1 and 8 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Study: NCT01676597
Drug: pentoxifylline and rifaximin
Normalized name: Rifaximin
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks
Study: NCT01676597
Drug: Pentoxifylline and placebo
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks
Study: NCT04047251
Drug: FF-10850 Topotecan Liposome Injection
Normalized name: topotecan Injection
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FF-10850 to be diluted and infused over 60 minutes.
Study: NCT00463268
Drug: alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alendronate 70 mg every 2 weeks
Study: NCT03153410
Drug: GVAX Pancreas Vaccine (GVAX)
Normalized name: GVAX
DrugBank: GVAX (DB17276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5x10\^8 cells, six intradermal (ID) injections~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle.
Study: NCT03153410
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg, intravenous (IV) infusion~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle.
Study: NCT03153410
Drug: IMC-CS4
Normalized name: IMC-18F1
DrugBank: Icrucumab (DB14824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg (dose level 1) or 100 mg (dose level 2), intravenous (IV) infusion~Patients receive neoadjuvant immunotherapy consisting of cyclophosphamide and pembrolizumab on day 1, IMC-CS4 on days 1, 8, and 15, and GVAX on day 2 of Cycles 1 and 2 (3 weeks/cycle). Patients will then undergo pancreaticoduodenectomy 2-3 weeks later, followed by standard of care adjuvant chemotherapy at the discretion of the primary oncologist. Patients may then receive 4 cycles (3 weeks/cycle) of adjuvant immunotherapy (same regimen as Cycles 1 and 2). Disease free patients may receive an additional 12 booster cycles (3 weeks/cycle) of immunotherapy consisting of pembrolizumab on day 1 of all 12 booster cycles, as well as cyclophosphamide on day 1 and GVAX on day 2 of the 6th and 12th booster cycle.
Study: NCT01303965
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Start on Day -3 and continue for 1 year
Study: NCT01303965
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Start on Day -3 and begin tapering on Day +100 until Day +180.
Study: NCT01303965
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Start between Day +30 and +120 and continue for 1 year.
Study: NCT00785525
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PBSC donors will receive 10 µg/kg of filgrastim subcutaneously each day of a five day mobilization schedule.
Study: NCT03288545
Drug: enfortumab vedotin (EV)
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous (IV) infusion on days 1 and 8 every 21 days
Study: NCT03288545
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion on day 1 every 21 days
Study: NCT03288545
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion on day 1 every 21 days
Study: NCT02265861
Drug: HCG
Normalized name: HCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03288545
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion on day 1 every 21 days
Study: NCT03288545
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion on days 1 and 8 every 21 days
Study: NCT00365157
Drug: Eribulin Mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT02448225
Drug: Fluorine F 18 L-glutamate Derivative BAY94-9392
Normalized name: L-Glutamate
DrugBank: Glutamic acid (DB00142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Undergo 18F-FSPG PET/CT
Study: NCT02187614
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02187614
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04263350
Drug: Atazanavir/Cobicistat
Normalized name: ATAZANAVIR/COBICISTAT
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified Dose on Specified Days
Study: NCT04263350
Drug: Reyataz Atazanavir
Normalized name: atazanavir Oral Capsule [Reyataz]
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified Dose on Specified Days
Study: NCT04263350
Drug: Cobicistat
Normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified Dose on Specified Days
Study: NCT01487577
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure
Study: NCT04246437
Drug: Carbidopa 200mg oral dose
Normalized name: carbidopa 50 MG / entacapone 200 MG / levodopa 200 MG [Stalevo]
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 minutes prior to the PET scan, patients will receive the 200mg oral dose of carbidopa to prevent peripheral \[18F\]FDOPA metabolism to increase signal-to-noise ratio of the imaging.
Study: NCT02744625
Drug: Higher doses of vasopressor therapy for a MAP of 75 mmHg
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04246437
Drug: Entacapone 400mg oral dose
Normalized name: Entacapone
DrugBank: Entacapone (DB00494)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 minutes prior to the PET scan, patients will receive the 400mg oral dose of entacapone to prevent peripheral \[18F\]FDOPA metabolism to increase signal-to-noise ratio of the imaging.
Study: NCT00633165
Drug: Brostallicin
Normalized name: Brostallicin
DrugBank: Brostallicin (DB06598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Brostallicin administered intravenously (IV) over 10 minutes at a dose of 10 mg/m2 on day one of a 21-day cycle. Safety and efficacy will be closely monitored and assessed.
Study: NCT00902187
Drug: Fesoterodine
Normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
Study: NCT04160052
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC or IV
Study: NCT04160052
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04217447
Drug: OAC + Aspirin 100mg od
Normalized name: aspirin 100 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive full-dose of OAC + Aspirin 100mg od during 24 to 48 months (until death or the end of the study : i.e. achievement of 2-year follow-up of the last included patient, maximum of 48-month followup for the first included patient)
Study: NCT04184492
Drug: GP-40081
Normalized name: GPS
DrugBank: Galinpepimut-S (DB17271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: biphasic insulin aspart 30 in doses 0.4 IU/kg
Study: NCT02744625
Drug: Propofol for light sedation
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol for light sedation
Study: NCT00501696
Drug: 4.5 mg Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low dose naltrexone 4,5mg on the multiple sclerosis quality of life inventory (MSQLI54)
Study: NCT00501696
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4,5mg low dose naltrexone on the multiple sclerosis quality of life inventory (MSQLI54)
Study: NCT04230954
Drug: Cabozantinib 40 MG oral once a day
Normalized name: cabozantinib 40 MG
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib 40 mg oral once a day
Study: NCT04230954
Drug: Pembrolizumab 200 mg IV every 3 weeks
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg IV every 3 weeks
Study: NCT04423185
Drug: Almonertinib 110 MG
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Almonertinib.
Study: NCT04423185
Drug: Dacomitinib 45 MG
Normalized name: dacomitinib 45 MG
DrugBank: Dacomitinib (DB11963)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Dacomitinib.
Study: NCT04423185
Drug: Alectinib 150 MG
Normalized name: alectinib 150 MG
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion will be administrated with Alectinib.
Study: NCT04423185
Drug: Crizotinib 250 MG
Normalized name: crizotinib 250 MG
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation will be administrated with Crizotinib.
Study: NCT04423185
Drug: Pyrotinib 160/80 MG
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with advanced rare tumors who failed to standardized treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib.
Study: NCT04423185
Drug: Imatinib 400 MG
Normalized name: imatinib 400 MG
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients with advanced rare tumors who failed to standardized treatment carrying CKIT mutation will be administrated with Imatinib.
Study: NCT04423185
Drug: Palbociclib 125mg
Normalized name: PALBOCICLIB 125MG TAB
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with advanced rare tumors who failed to standardized treatment carrying CDKN2A mutation will be administrated with palbociclib.
Study: NCT04423185
Drug: Vemurafenib 240 MG
Normalized name: vemurafenib 240 MG
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with advanced rare tumors who failed to standardized treatment carrying BRAF mutation will be administrated with Vemurafenib.
Study: NCT04423185
Drug: Sintilimab 100MG
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with advanced rare tumors who failed to standardized treatment carrying no targeted alterations will be administrated with Sintilimab.
Study: NCT04423185
Drug: Atezolizumab 1680 MG
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients with BRAF mutation treated with vemurafenib, after acquired resistance, will combine vemurafenib with atezolizumab.
Study: NCT02378805
Drug: ACE-inhibitor
Normalized name: C1-inhibiting factor
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: observational study
Study: NCT02378805
Drug: Paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: observational study!